Discovery of A-1331852, a First-in-Class, Potent and Orally-Bioavailable BCL-XL Inhibitor

Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-XL inhibitor that selectively and potently induces apoptosis in BCL-XL dependent tumor cells. This molecule was gen...